Brief: Neurotech International Requests US FDA Orphan Drug Designation For Rett Syndrome
30/08/2024 02:39
Aug 30 (Reuters) - Neurotech International Ltd NTI.AX :
* US FDA ORPHAN DRUG DESIGNATION REQUESTED FOR RETT SYNDROME
Further company coverage: NTI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt